HSAQ vs. NSPR, SEPA, MGRM, DRIO, ICCM, NVNO, AMIX, PDEX, APYX, and LUCD
Should you be buying Health Sciences Acquisitions Co. 2 stock or one of its competitors? The main competitors of Health Sciences Acquisitions Co. 2 include InspireMD (NSPR), SEP Acquisition (SEPA), Monogram Orthopaedics (MGRM), DarioHealth (DRIO), IceCure Medical (ICCM), enVVeno Medical (NVNO), Autonomix Medical (AMIX), Pro-Dex (PDEX), Apyx Medical (APYX), and Lucid Diagnostics (LUCD). These companies are all part of the "surgical & medical instruments" industry.
Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
InspireMD received 2 more outperform votes than Health Sciences Acquisitions Co. 2 when rated by MarketBeat users.
InspireMD has a consensus price target of $4.85, indicating a potential upside of 110.87%. Given InspireMD's higher probable upside, analysts plainly believe InspireMD is more favorable than Health Sciences Acquisitions Co. 2.
89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 44.8% of InspireMD shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Comparatively, 29.7% of InspireMD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, InspireMD had 6 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 7 mentions for InspireMD and 1 mentions for Health Sciences Acquisitions Co. 2. Health Sciences Acquisitions Co. 2's average media sentiment score of 0.76 beat InspireMD's score of -0.76 indicating that Health Sciences Acquisitions Co. 2 is being referred to more favorably in the media.
Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to InspireMD's net margin of -320.97%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat InspireMD's return on equity.
Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than InspireMD.
Summary
InspireMD beats Health Sciences Acquisitions Co. 2 on 7 of the 13 factors compared between the two stocks.
Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Sciences Acquisitions Co. 2 Competitors List
Related Companies and Tools
